Skinvisible Pharmaceuticals has received US patent for combining retinoic acid with its patented polymer delivery system, Invisicare.
The patent issued by the United States Patent and Trademark Office (USPTO) under the name of "Methods for Stabilizing Retinoids, Retinoid Containing Composition, and Methods of Using a Retinoid Containing Composition," will last till 14 April 2029.
The patent further substantiates Invisicare benefits and also covers retinoid stabilization method and a retinoid composition.
Skinvisible Pharmaceuticals president and CEO Terry Howlett said the patent increases the depth of intellectual property protection for acne formulations.
"This patent provides potential licensees with a further layer of exclusivity and will assist Skinvisible as it actively seeks partnering, licensing and co-development arrangements globally to maximize the potential of this recently issued patent," Howlett added.